Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

PURPOSE: Immune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI resumption. METHODS: This retrospective multicenter study examined patients who resumed ICI therapy aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Sbeih, Hamzah, Ali, Faisal S., Naqash, Abdul Rafeh, Owen, Dwight H., Patel, Sandipkumar, Otterson, Gregory A., Kendra, Kari, Ricciuti, Biagio, Chiari, Rita, De Giglio, Andrea, Sleiman, Joseph, Funchain, Pauline, Wills, Beatriz, Zhang, Jiajia, Naidoo, Jarushka, Philpott, Jessica, Gao, Jianjun, Subudhi, Sumit K., Wang, Yinghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800279/
https://www.ncbi.nlm.nih.gov/pubmed/31163011
http://dx.doi.org/10.1200/JCO.19.00320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800279/
https://www.ncbi.nlm.nih.gov/pubmed/31163011
http://dx.doi.org/10.1200/JCO.19.00320

Ejemplares similares